Category Archives: Poor Research

Recent in: Poor Research

The new draft of the Infectious Disease Society of America (IDSA) guidelines open for public comment for 45 days.

The IDSA has presented their draft guidelines which with a brief scan appear not much different then their old controversial poorly evidenced guidelines.  Much of the same old players and 3 token patients. Typical unequal representation. Public comments close August 10th. Take your time, make notes before you enter their controlled comment format process as you have to submit all Continues →

The Scientist – Opinion: The “Money Culture” in Academic Biomedical Research

[CanLyme Note: This for profit money drive takes medical research away from cure to ‘a drug for every symptom’. In Canada, relative to Lyme disease, the private Association of Medical Microbiology and Infectious Disease of Canada (AMMI), is an extension of the ‘do not cure’ medical money machine. They offer opinion and poorly designed research to support the ‘do not treat Continues →

Lyme advocates say Canada offers “toxic tokenism” to patients

The Canadian government recently announced new investment in Lyme disease research. However, Canadian Lyme advocates fear that the patient voice will be excluded from the decision-making process. In the following article, the Canadian Lyme Consortium (CLC)–made up of advocates, patients, researchers and practitioners–offers background and context. By Vett Lloyd, PhD; Liz Zubek, MD, CCFP FCFP; Sue Faber and Jennifer Kravis, co-founders, LymeHope; Janet Sperling, CanLyme; Linda Kelso, Continues →

Anti-science old guard taking last dying breaths of continuing to misinform physicians using tax payer dollars

Here is their opinion article title, amazing in 2017 how poorly they reference their evidence… “False and Misleading Information about Lyme Disease”   Here is one of their uniformed statements, “Persistent, unexplained subjective symptoms such as chronic fatigue and pain are common in the general population. Annual surveys by the Centers for Disease Control and Prevention (CDC) indicate that approximately Continues →

Flunk the Lyme test? Just wait and get sicker

January, 2017, Huffington Post Sin Lee, a pathologist and scientist, believes the deck is stacked in the quest to air new ideas on Lyme disease. Too many science journals telling him to take his research elsewhere. Too many deftly worded rejections. Too little inclination to engage in a fair fight over the facts and fiction of Lyme disease. Dr. Lee’s Continues →

CanLyme director responds to Canadian Medical Association Journal article

Response to Doctors Gregson and Quach Robert G. Murray, DDS, Director, CanLyme Re: “The Lyme law” Zubek, 187:520-521doi:10.1503/cmaj.115-0029 The problem with Lyme disease in Canada will only continue to grow to the point where the numbers affected will simply overwhelm the idea that Lyme Borreliosis (LB) is hard to catch and easy to treat with a short round of antibiotics. Continues →

Doctor comments on Lyme disease treatment

[CanLyme note: It is very common for mainstream physicians who subscribe to the Infectious Disease Society of America guidelines to design studies in such a fashion that the outcome is pre-determined.  These studies have no value, nor scientific merit.  The divide is created intentionally.] Infectious Disease doctor, Sam Donta, responds to article, To the Editor: I am responding to the Continues →

A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library

Frontiers in Microbiology, May 23, 2016 Although currently recommended antibiotics for Lyme disease such as doxycycline or amoxicillin cure the majority of the patients, about 10–20% of patients treated for Lyme disease may experience lingering symptoms including fatigue, pain, or joint and muscle aches. Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body Continues →

Watch CTV news interview of Dr. Todd Hatchette. A very good example of how opinion, not science, is driving Lyme borreliosis policy in Canada… in spite of evidence presented by experts in Ottawa, May 15th to 17th, 2016.

[Lyme disease is actually Lyme borreliosis. an infection caused by many different strains/genotypes of Borrelia bacteria] How can one rationalize making progress from the patient’s expert perspective when officially, by tax payer funded microbiologists, opinion is put forward as fact with no supporting science. Dr. Todd Hatchette attended the recent three day conference in Ottawa during which a wide diversity Continues →

New Lyme Disease Study Reveals Strong Reporting Bias

David Michael Conner Huffington Post On March 31, the New England Journal of Medicine published a study that concludes, “In patients with persistent symptoms attributed to Lyme disease, longer-term antibiotic treatment did not have additional beneficial effects on health-related quality of life beyond those with shorter-term treatment.” Read full article

Physicians and patients weigh in on latest poorly designed study that raises the question, “Why?”, and, “Who is driving this spin?”

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease Comment “Persister research needs to account for morphological variability of Lyme The patient population studied was already a group that had shown persistence of disease. These would be “treatment failures” and more difficult cases. Even in this difficult population every group who received 2 weeks of IV ceftriaxone made Continues →

Chronic Lyme European PLEASE Trial—You know it’s spin when treatment “success” is called “failure”?

March 30th, 2016 Today a widely anticipated clinical trial on chronic Lyme disease from Europe called PLEASE was published in the New England Journal of Medicine (NEJM).  The press has given the trial a twenty trumpet salute with a MedPage headline reading “Long-Term Antibiotics Fail Again in Lyme Disease–Focus on Lyme and antibiotics for persistent symptoms called unhelpful.”  Here’s the Continues →

Cardiac Tropism of Borrelia burgdorferi: An Autopsy Study of Sudden Cardiac Death Associated with Lyme Carditis.

[ CanLyme note: “Although rare”, yet they state in the same breath that “sudden cardiac death caused by Lyme disease might be an under-recognized entity”.  In other words, they have no idea because in the past decades they have not been looking and nor was Lyme disease considered in similar sudden cardiac deaths. The standard Borrelia burgdorferi serology is a Continues →